What is Senti Biosciences Cash, Cash Equivalents, Marketable Securities?
Senti Biosciences's quarterly cash, cash equivalents, marketable securities
declined
from Sep. 2023 ($39.43 Mil) to Dec. 2023 ($35.93 Mil) but then
stayed the same
from Dec. 2023 ($35.93 Mil) to Mar. 2024 ($23.72 Mil).
Senti Biosciences's annual cash, cash equivalents, marketable securities
increased
from Dec. 2021 ($56.03 Mil) to Dec. 2022 ($98.56 Mil) but then
declined
from Dec. 2022 ($98.56 Mil) to Dec. 2023 ($35.93 Mil).
Senti Biosciences Cash, Cash Equivalents, Marketable Securities Historical Data
The historical data trend for Senti Biosciences's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Senti Biosciences Cash, Cash Equivalents, Marketable Securities Related Terms
Thank you for viewing the detailed overview of Senti Biosciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Senti Biosciences (Senti Biosciences) Business Description
Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNTI has been successfully added to your 